Markers of inflammation and blood-clotting tied to hazards of intermittent HIV treatment

October 22, 2008

Episodic treatment of HIV/AIDS with antiretroviral drugs increases the overall risk of death when compared with continuous antiretroviral treatment (ART), but the reasons why have been unknown. Now, researchers have found that higher levels of certain markers of inflammation and blood-clotting are strongly associated with intermittent ART and with a higher risk of death from non-AIDS diseases.

The new report, published in the open access journal PLoS Medicine, is a further analysis of the "Strategies for Management of Antiretroviral Therapy" (SMART) study supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (http://www3.niaid.nih.gov/news/newsreleases/2006/smart06). SMART, which ended in 2006, compared the standard practice of continuous ART to suppress HIV in infected individuals with episodic ART based on CD4+ T-cell counts. The goal was to determine whether reducing exposure to antiretroviral drugs, which may have toxic side effects and can engender drug resistance, would be equally or more beneficial than suppressing HIV continuously. Unexpectedly, those who received episodic ART were more than twice as likely to develop disease or die, and the study ended early as a result.

Reflecting on this outcome, James D. Neaton, Ph.D., of the University of Minnesota, and his colleagues hypothesized that pausing ART and allowing HIV levels to rise stimulated inflammation and blood clotting in some patients, which could lead to disease or death.

To test their hypothesis, the scientists examined blood samples from the SMART trial for proteins that are biological markers of inflammation and blood clotting. They found that people who began the study with relatively higher levels of the biomarkers interleukin-6 (IL-6) and D-dimer were at greater risk of death than other study participants. They also found that IL-6 and D-dimer levels rose significantly in the intermittent-treatment group compared to the continuous treatment group after just one month of study.

Based on these observations, the authors conclude that HIV-infected patients who have relatively high levels of IL-6 and D-dimer are at greater risk of death. Most of the deaths in SMART were attributed to non-AIDS-related diseases, the authors write, and giving intermittent ART to volunteers who began that study with elevated levels of these biomarkers may have further increased their risk of death.

NIH/National Institute of Allergy and Infectious Diseases

---

---

	LC-MS in Drug Bioanalysis by Q. Alan Xu (Editor), Timothy L. Madden (Editor) Clinical pharmacology plays an important role in today’s medicine. Due to the high sensitivity, selectivity, and affordability of a mass spectrometer (MS), the high performance liquid chromatography – mass spectrometry (LC-MS) analytical technique is widely used in the determination of drugs in human biological matrixes for clinical pharmacology. Specifically, LC-MS is used to analyze: anticancer drugs antidementia drugs antidepressant drugs antiepileptic drugs antifundal drug antimicrobial drugs antipsychotic drugs antiretroviral drugs anxiolytic/hypnotic drugs cardiac drugs drugs for addiction immunosuppressant drugs mood stabilizer drugs This book will primarily cover the various methods of validation for LC-MS techniques and applications used in modern clinical pharmacology.
	Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities by Committee on Examining the Probable Consequences of Alternative Patterns of Widespread Antiretroviral Drug Use in Resource-Constrained Settings (Author), James Curran (Editor), Haile Debas (Editor), Monisha Arya (Editor), Patrick Kelley (Editor), Stacey Knobler (Editor), Leslie Pray (Editor) An estimated forty million people carry the human immunodeficiency virus (HIV), and five million more become newly infected annually. In recent years, many HIV-infected patients in wealthy nations have enjoyed significantly longer, good-quality lives as a result of antiretroviral therapy (ART). However, most infected individuals live in the poorest regions of the world, where ART is virtually nonexistent. The consequent death toll in these regions - especially sub-Saharan Africa - is begetting economic and social collapse. To inform the multiple efforts underway to deploy antiretroviral drugs in resource-poor settings, the Institute of Medicine committee was asked to conduct an independent review and assessment of rapid scale-up ART programs. It was also asked to identify the components...
	Tables: Antiretroviral Agents (Postgraduate Medicine) by JTE Multimedia Abstract: National Institutes of Health. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV–infected adults and adolescents. HIV/AIDS Treatment Information Service. January 29, 2008. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentsGL.pdf. Accessed October 9, 2008. Original Publication Date: November 2008
	DESIGNING SALVAGE ANTIRETROVIRAL REGIMENS: Some basic guidelines and use of resistance testing (Postgraduate Medicine1) by JTE Multimedia In the field of HIV medicine, the term "salvage regimen" refers to one that is constructed for a patient in whom multiple previous regimens have been unsuccessful, for a wide variety of reasons. Although such regimens may have unproved efficacy, they are based on some solid scientific data or principles. In this article, the authors discuss the current state of genotyping and phenotyping used for resistance testing, the challenges involved in interpreting the data they provide, and factors to keep in mind when considering a switch to a different treatment regimen. Hardy WD, Hitt RS. Designing salvage antiretroviral regimens: some basic guidelines and use of resistance testing. Original Publication Date: April 2000
	Delmar Nurse's Drug Handbook 2012 Edition (Delmar's Nurse's Drug Handbook) by George R. Spratto (Author), Adrienne L. Woods (Author) Put the latest edition of today's most trusted drug reference guide in your hands with DELMAR NURSE'S DRUG HANDBOOK™ 2012 EDITION. This essential resource clearly describes the most important information for over 770 of the latest and most common FDA-approved drugs. Each entry provides a wealth of information concerning drug action, pharmacokinetics, dosage, interactions, and contraindications. Clear guidelines are also provided for administration of drugs, communication with clients, and nursing considerations. This edition offers even more convenience with an iPhone/iPod touch Application that places the complete drug guide at your fingertips with enhanced search options.
	Delmar Nurse's Drug Handbook 2011: Special 20 Year Anniversary (Delmar's Nurse's Drug Handbook) by George R. Spratto (Author), Adrienne L. Woods (Author) For 20 years, Delmar's Nurse's Drug Handbook™ continues to be an essential resource for the most important drug information with over 1,000 of the latest and most common FDA-approved drugs, Each entry provides a wealth of facts concerning drug action, dosage, interactions, and contraindications. Clear guidelines are also provided for administration of drugs, communication with clients, and nursing considerations. The Delmar Nurse's Drug Handbook™2011: Special 20-Year Anniversary Edition highlights prevention of medication errors and clinical accountability like no other drug resource, making it a trusted resource for nursing students, practicing nurses, and other health care professionals.
	Poisoning and Drug Overdose, Sixth Edition (Olson, Poisoning and Drug) by Kent Olson (Author) “Poisoning & Drug Overdose belongs in every emergency physician’s workroom.” --Academic Emergency Medicine reviewing earlier edition “…a great addition to any emergency department library when rapid reference is needed to treat and diagnose the poisoned patient.” -- Annals of Emergency Medicine reviewing earlier edition An instant-answer guide you can turn to for on-the-spot treatment of poisoning and drug overdose Poisoning & Drug Overdose, Sixth Edition delivers critical information on effective diagnosis and treatment of drug-related emergencies and chemical exposures. Divided into four sections, easily identified by dictionary-style tabs: Section I covers initial emergency management, including treatment of complications; physical and laboratory diagnosis;...
	Gale Encyclopedia of Medicine: Antiretroviral drugs by Samuel D. Uretsky PharmD (Author) The article is excerpted from Gale Encyclopedia of Medicine. Consult the second edition of this authoritative, comprehensive, in-depth medical guide for information on more than 1,700 medical topics in language accessible to adult laypersons. Presented in a single alphabetical sequence, articles range in length from one or two paragraphs for minor topics, to several pages or more for major topics. Disease/disorder articles typically cover definition; description; causes and symptoms; diagnosis; treatments; prevention; and more. Test/treatment articles typically cover definition; purposes; precautions; preparation; risks; normal and abnormal results; and much more. This second edition includes more than 200 new entries, 300 updated entries, approximately 650 color images...
	Gale Encyclopedia of Nursing and Allied Health: Antiretroviral drugs by PharmD Samuel Uretsky (Author) The article is excerpted from Gale Encyclopedia of Nursing and Allied Health. This 5-vol. set provides more than 850 entries covering topics in nursing and allied health written for students and professionals in the field. Alphabetically arranged entries cover topics in body systems and functions, conditions and common diseases, issues and theories, techniques and practices, and devices and equipment. The Encyclopedia covers all major health professions, including nursing, physical therapy, occupational therapy, respiratory therapy, medical lab technology, emergency medical technology, dental assistance, pharmacology and nutrition. In addition, the set features approximately 400 photographs and illustrations; appendices of related organizations, agencies and associations;...
	Africa: problems getting antiretrovirals for trials.(ethics of drug research in developing countries): An article from: AIDS Treatment News by John S. James (Publisher) This digital document is an article from AIDS Treatment News, published by John S. James on May 30, 2003. The length of the article is 577 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Africa: problems getting antiretrovirals for trials.(ethics of drug research in developing countries) Publication: AIDS Treatment News (Newsletter) Date: May 30, 2003 Publisher: John S. James Page: 5(2) Distributed by Thomson Gale